Lindsey R. Sangaralingham

Lindsey R. Sangaralingham

Auto-generated profile, based on publicly available information

Lindsey R. Sangaralingham

Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2019 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
TDTimothy M. Dempsey
Timothy M. Dempsey
LSLindsey R. Sangaralingham
Lindsey R. Sangaralingham
XYXiaoxi Yao
Xiaoxi Yao
DSDarshak Sanghavi
Darshak Sanghavi
NSNilay D. Shah
Nilay D. Shah
ALAndrew H. Limper
Andrew H. Limper
Rationale: Since their approval, there has been no real-world or randomized trial evidence evaluating the effect of the antifibrotic medications pirfenidone and nintedanib on clinically important outcomes such as mortality and hospitalizations. Objectives: To evaluate the clinical effectiveness of the antifibrotic medications pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis. Methods: Using a large U.S. insurance database, we identified 8,098 patients with idiopathic pulmonary fibrosis between October 1, 2014 and March 1, 2018. A one-to-one propensity score–matched cohort was created to compare patients treated with antifibrotic medications (n = 1,255) with those not on treatment (n = 1,255). The primary outcome was all-cause mortality. The secondary outcome was acute hospitalizations. Subgroup analyses were performed to evaluate mortality differences by drug. Measurements and Main Results: The use of antifibrotic medications was associated with a decreased risk of all-cause mortality (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.62–0.98; P value = 0.034). However, this association was present only through the first 2 years of treatment. There was also a decrease in acute hospitalizations in the treated cohort (HR, 0.70; 95% CI, 0.61–0.80; P value <0.001). There was no significant difference in all-cause mortality between patients receiving pirfenidone and those on nintedanib (HR, 1.14; 95% CI, 0.79–1.65; P = 0.471). Conclusions: Among patients with idiopathic pulmonary fibrosis, antifibrotic agents may be associated with a lower risk of all-cause mortality and hospitalization compared with no treatment. Future research should test the hypothesis that these treatments reduce early, but not long-term, mortality as demonstrated in our study.

24 October 2019 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
BDBrent R. DeGeorge
Brent R. DeGeorge
HHHolly K. Van Houten
Holly K. Van Houten
RMRaphael Mwangi
Raphael Mwangi
LSLindsey R. Sangaralingham
Lindsey R. Sangaralingham
ALA. Noelle Larson
A. Noelle Larson
SKSanjeev Kakar
Sanjeev Kakar
Background: The purpose of the present study was to identify trends in management and to compare the outcomes and complications following nonoperative and operative management (including external fixation, closed reduction and percutaneous pinning, and open reduction and internal fixation) for distal radial fractures in patients ≥65 years of age. Methods: We performed a retrospective analysis, with use of the OptumLabs Data Warehouse database, of patients ≥65 years of age who had been managed for a distal radial fracture between 2009 and 2014 (as indicated by diagnosis codes according to the International Classification of Diseases, Ninth Revision, Clinical Modification). Ninety-day and 1-year complication rates per 1,000 fractures were analyzed overall and by treatment modality. Results: Thirteen thousand, seven hundred and thirteen distal radial fractures were analyzed. The overall 90-day complication rate was 36.5 per 1,000 fractures, and the 1-year upper-extremity-specific complication rate was 236.2 and 307.5 per 1,000 fractures for nonoperative and operative management, respectively. Overall, post-injury stiffness was the most common 1-year upper-extremity-specific complication (incidence, 11.5%). There was no significant difference between operative and nonoperative management in terms of 90-day complication rates. However, operative management had a higher 1-year complication rate than nonoperative management (307.5 versus 236.2 per 1,000 fractures). Overall, the 5 most common upper-extremity-specific complications following operative treatment of distal radial fracture were stiffness (16.0%), chronic regional pain syndrome (9.9%), median neuropathy (8.0%), implant-related complications (3.8%), and tendon-related complications (2.8%). Stiffness was significantly more frequent following operative management (16.0% versus 9.8%; p < 0.01). Conclusions: Operative management of a distal radial fracture should be carefully considered when discussing treatment options with patients ≥65 years of age. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

25 January 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
JRJoseph S Ross
Joseph S Ross
SRStefanie Rohde
Stefanie Rohde
LSLindsey Sangaralingham
Lindsey Sangaralingham
JBJuan P Brito
Juan P Brito
LCLauren Choi
Lauren Choi
NSNilay D Shah
Nilay D Shah
Context Generic drugs account for 9 out of 10 prescriptions dispensed in the U.S., but for a fewer proportion of commonly prescribed thyroid hormone replacement therapies. Objective Characterize temporal patterns of generic and brand-name thyroid hormone drug use, including patient and prescriber characteristics associated with brand-name use. Design and Setting Cross-sectional longitudinal analysis of national data from a large administrative claims database from January 2007 through December 2016. Patients Adults with insurance coverage through commercial, Medicare Advantage and Medicare Part D health plans. Main Outcome Measures Generic and brand-name thyroid hormone drug use. Results From 2007 to 2016, the annual number of thyroid hormone treatment pharmacy fills increased from 8,905,836 in 2007 to 11,613,923 in 2016, 73.6% of which were for generic levothyroxine, 23.4% for brand-name levothyroxine, and the remaining for other formulations. Dispensing of generic thyroid hormone drugs increased from 59.8% in 2007 to 84.9% in 2016 and was consistently higher among Medicare Advantage and Medicare Part D when compared with the commercial beneficiary population. For all three beneficiary populations, use of brand-name products was less common among older adults and more common among women and those receiving prescriptions from endocrinologists, as well as more common among those of white race and with greater household income for the Medicare Advantage and commercial beneficiary populations (p-values <0.001). Conclusions Brand-name thyroid hormone product use declined from 2007 to 2016 among three large, national insurer beneficiary populations. While certain patient characteristics were associated with brand-name use, prescriber specialty was the strongest predictor.

13 May 2022 in JMIR Formative Research
Verified
Journal Article
Open access
PSPravesh Sharma
Pravesh Sharma
ASAnthony R Sinicrope
Anthony R Sinicrope
PSPamela Sinicrope
Pamela Sinicrope
TBTabetha A Brockman
Tabetha A Brockman
NRNicole M Reinicke
Nicole M Reinicke
CPChristi Patten
Christi Patten
Background: During the COVID-19 pandemic, to prevent the spread of the virus, federal regulatory barriers around telemedicine were lifted, and health care institutions encouraged patients to use telemedicine, including video appointments. Many patients, however, still chose face-2-face (f2f) appointments for nonemergent clinical care. Objective: We explored patients’ personal and environmental barriers to the use of video appointments from April 2020 to December 2020. Methods: We conducted qualitative telephone interviews of Mayo Clinic patients who attended f2f appointments at the Mayo Clinic from April 2020 to December 2020 but did not utilize Mayo Clinic video appointment services during that time frame. Results: We found that, although most patients were concerned about preventing COVID-19 transmission, they trusted Mayo Clinic to keep them safe when attending f2f appointments. Many expressed that a video appointment made it difficult to establish rapport with their providers. Other common barriers to video appointments were perceived therapeutic benefits of f2f appointments, low digital literacy, and concerns about privacy and security. Conclusions: Our study provides an in-depth investigation into barriers to engaging in video appointments for nonemergent clinical care in the context of the COVID-19 pandemic. Our findings corroborate many barriers prevalent in the prepandemic literature and suggest that rapport barriers need to be analyzed and problem-solved at a granular level.

30 January 2017 in Academic Emergency Medicine
Verified
Journal Article
Closed access
MBM. Fernanda Bellolio
M. Fernanda Bellolio
LSLindsey R. Sangaralingham
Lindsey R. Sangaralingham
SSStephanie R. Schilz
Stephanie R. Schilz
CNClaire M. Noel‐Miller
Claire M. Noel‐Miller
KLKeith D. Lind
Keith D. Lind
EHErik P. Hess
Erik P. Hess

1 October 2021 in Annals of the American Thoracic Society
Verified
Journal Article
Open access
TDTimothy M. Dempsey
Timothy M. Dempsey
SPStephanie Payne
Stephanie Payne
LSLindsey Sangaralingham
Lindsey Sangaralingham
ALAndrew Limper
Andrew Limper